GRDN

Guardian Pharmacy Services, Inc. (GRDN) - Q1 2025 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2025. Guardian Pharmacy Services, Inc. is a leading pharmacy services provider specializing in long-term health care facilities (LTCFs), with a strategic focus on assisted living facilities (ALFs) and behavioral health facilities (BHFs). As of March 31, 2025, the company operated 51 pharmacies serving approximately 189,000 residents across 7,000 LTCFs in 38 states. The company completed its Initial Public Offering (IPO) and Corporate Reorganization on September 27, 2024, transitioning from a private LLC structure to a public corporation.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 19.6% year-over-year to $329.3 million. This was driven by $21.1 million from acquisitions completed in 2024 and $32.8 million from organic growth. The number of residents served grew from 164,000 to 189,000.
• Profitability: Operating income rose 64% to $13.0 million. Net income attributable to the Company was $9.4 million, compared to $0 in Q1 2024 due to the pre-IPO corporate structure where income was attributed to non-controlling interests.
• Expense Management: Selling, general, and administrative (SG&A) expenses increased 8.9% to $51.3 million but decreased as a percentage of revenue from 17.1% to 15.6%. This improvement was largely due to a $2.0 million decrease in share-based compensation expense following the IPO.
• Interest Expense: Interest expense dropped 77.8% to $0.17 million as the company had no outstanding balances on its credit facility during Q1 2025, compared to significant borrowings in Q1 2024.
• Tax Provision: The company recorded an income tax provision of $3.8 million (29.2% effective rate) in Q1 2025. No tax provision was recorded in Q1 2024 as the entity was taxed as a partnership prior to the Corporate Reorganization.

Guidance, Outlook, and Risks

Outlook and Liquidity: Management believes existing cash ($14.0 million), expected cash from operations, and the available $40 million line of credit (with an option to increase to $75 million) are sufficient to meet working capital and capital expenditure needs for the next 12 months. The company continues to pursue growth through both organic expansion and acquisitions.

Key Risks and Contingencies:

• Regulatory and Reimbursement: Risks include government efforts to lower pharmaceutical costs and changes in healthcare laws affecting pharmacy reimbursements.
• Operational Risks: Exposure to supply chain disruptions, cybersecurity threats, and the ability to retain senior management and pharmacy professionals.
• Legal Proceedings: The company is subject to ordinary course legal proceedings. Legal expenses were $0.5 million in Q1 2025 compared to $1.7 million in Q1 2024.
• Stock Volatility: The Class A common stock may experience substantial volatility due to relatively lower trading volumes and a limited public float.

Investor Verification Checklist

• Acquisition Integration: Verify the performance of pharmacies acquired in 2024 to ensure they are meeting revenue and earnings targets required for contingent earnout payments (up to $2.7 million).
• Share Conversion Schedule: Monitor the automatic conversion of Class B common stock to Class A common stock, with 25% converting on March 28, 2025 (completed), and subsequent dates in September 2025, March 2026, and September 2026.
• Working Capital Trends: Review the increase in accounts receivable and inventory levels relative to revenue growth to ensure efficient collection and inventory management.
• Share-Based Compensation: Track the remaining unamortized share-based compensation costs ($18.4 million) and their impact on future earnings as awards vest.
• Debt Covenants: Confirm compliance with financial ratios required by the Credit Facility with Regions Bank, which matures in April 2027.